Hubei Jumpcan Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Hubei Jumpcan Pharmaceutical Co Ltd cash flow-to-debt ratio. Hubei Jumpcan Pharmaceutical Co Ltd (600566) has a Cash Flow-to-Debt Ratio of -0.09x as of September 2025, meaning its operating cash flow of CN¥-243.75 Million could theoretically repay 0% of its total liabilities (CN¥2.68 Billion) in one year. Check how high is Hubei Jumpcan Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Hubei Jumpcan Pharmaceutical Co Ltd (2000–2025)
Cash flow-to-debt ratio of Hubei Jumpcan Pharmaceutical Co Ltd from 2000 to 2025. Historical debt coverage capacity for Hubei Jumpcan Pharmaceutical Co Ltd across 26 annual periods. Check total reinvestment intensity of Hubei Jumpcan Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Hubei Jumpcan Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (2000–2025)
Hubei Jumpcan Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 2000 to 2025. Year-by-year debt coverage analysis for Hubei Jumpcan Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Hubei Jumpcan Pharmaceutical Co Ltd (600566) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.39x | CN¥1.20 Billion | CN¥3.07 Billion | ▼ -33.0% |
| 2024 | 0.58x | CN¥2.18 Billion | CN¥3.73 Billion | ▼ -19.6% |
| 2023 | 0.73x | CN¥3.46 Billion | CN¥4.77 Billion | ▲ +0.4% |
| 2022 | 0.72x | CN¥2.62 Billion | CN¥3.63 Billion | ▲ +14.4% |
| 2021 | 0.63x | CN¥1.89 Billion | CN¥3.00 Billion | ▼ -2.4% |
| 2020 | 0.65x | CN¥1.78 Billion | CN¥2.75 Billion | ▼ -22.8% |
| 2019 | 0.84x | CN¥2.15 Billion | CN¥2.56 Billion | ▲ +14.8% |
| 2018 | 0.73x | CN¥1.71 Billion | CN¥2.34 Billion | ▲ +38.9% |
| 2017 | 0.53x | CN¥1.19 Billion | CN¥2.26 Billion | ▼ -25.1% |
| 2016 | 0.70x | CN¥913.10 Million | CN¥1.30 Billion | ▼ -5.1% |
| 2015 | 0.74x | CN¥645.48 Million | CN¥872.59 Million | ▲ +27.7% |
| 2014 | 0.58x | CN¥616.11 Million | CN¥1.06 Billion | ▲ +73.9% |
| 2013 | 0.33x | CN¥287.16 Million | CN¥862.04 Million | ▲ +519.2% |
| 2012 | 0.05x | CN¥27.01 Million | CN¥502.07 Million | ▲ +5590.6% |
| 2011 | 0.00x | CN¥411.24K | CN¥435.00 Million | ▼ -99.4% |
| 2010 | 0.15x | CN¥51.13 Million | CN¥342.89 Million | ▲ +880.6% |
| 2009 | 0.02x | CN¥4.92 Million | CN¥323.37 Million | ▼ -78.7% |
| 2008 | 0.07x | CN¥23.05 Million | CN¥323.43 Million | ▼ -41.1% |
| 2007 | 0.12x | CN¥36.72 Million | CN¥303.49 Million | ▲ +757.6% |
| 2006 | 0.01x | CN¥4.24 Million | CN¥300.69 Million | ▼ -94.4% |
| 2005 | 0.25x | CN¥63.38 Million | CN¥251.96 Million | ▲ +249.3% |
| 2004 | -0.17x | CN¥-37.74 Million | CN¥223.98 Million | ▼ -1481.1% |
| 2003 | 0.01x | CN¥2.24 Million | CN¥183.92 Million | ▼ -91.8% |
| 2002 | 0.15x | CN¥22.00 Million | CN¥148.17 Million | ▲ +166.1% |
| 2001 | 0.06x | CN¥7.43 Million | CN¥133.08 Million | ▼ -80.4% |
| 2000 | 0.28x | CN¥23.73 Million | CN¥83.37 Million | — |